CO4480106A1 - Compuestos de quinolina y quinazolina utiles en terapia - Google Patents
Compuestos de quinolina y quinazolina utiles en terapiaInfo
- Publication number
- CO4480106A1 CO4480106A1 CO96066994A CO96066994A CO4480106A1 CO 4480106 A1 CO4480106 A1 CO 4480106A1 CO 96066994 A CO96066994 A CO 96066994A CO 96066994 A CO96066994 A CO 96066994A CO 4480106 A1 CO4480106 A1 CO 4480106A1
- Authority
- CO
- Colombia
- Prior art keywords
- ring
- alcoxi
- group
- heteroatomes
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA INVENCION PROPORCIONA COMPUESTOS DE FORMULA I, EN LA QUE R1 REPRESENTA ALCOXI C1-4 OPCIONALMENTE SUSTITUIDO CON UNO O MAS ATOMOS DE FLUOR; R2 REPRESENTA H o ALCOXI C1-6 OPCIONALMENTE SUSTI- TUIDO CON UNO O MAS ATOMOS DE FLUOR; R3 REPRESENTA UNO O MAS GRUPOS SELECCIONADOS INDE- PENDIENTEMENTE ENTRE H, HALOGENO, ALCOXI C1-4 Y CF3; ADEMAS, R2 Y UN GRUPO R3 PUEDEN REPRESENTAR CON- JUNTAMENTE -OCH2-, ESTANDO UNIDO EL GRUPO METILENO A LA POSICION ORTO DEL ANILLO FENILICO COLGANTE; R4 REPRESENTA UN ANILLO HETEROCICLICO DE 4, 5 O 6 MIEMBROS QUE CONTIENE 1 O 2 HETEROATOMOS SELECCIO- NADOS ENTRE N, O y S, ESTANDO EL ANILLO OPCIONAL- MENTE CONDENSADO A UN ANILLO DE BENCENO O A UN A- NILLO HETEROCICLICO DE 5 o 6 MIEMBROS QUE CONTIENE 1 o 2 HETEROATOMOS SELECCIONADOS ENTRE N, O y S, ESTANDO EL SISTEMA DE ANILLO GLOBAL OPCIONALMENTE SUSTITUIDO; X REPRESENTA CH o N; Y L ESTA AUSEN- TE O REPRESENTA UN GRUPO CICLICO O UN GRUPO DE CA- DENA ABIERTA; Y SALES FARMACEUTICAMENTE ACEPTA- BLES DE LOS MISMOS. LOS COMPUESTOS DE FORMULA I SON UTILES EN EL TRATAMIENTO DE, ENTRE OTROS, LA HIPERPLASIA PROSTATICA BENIGNA. FIGURA 1
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9526546.8A GB9526546D0 (en) | 1995-12-23 | 1995-12-23 | Compounds useful in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4480106A1 true CO4480106A1 (es) | 1997-07-09 |
Family
ID=10786091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO96066994A CO4480106A1 (es) | 1995-12-23 | 1996-12-20 | Compuestos de quinolina y quinazolina utiles en terapia |
Country Status (34)
Country | Link |
---|---|
US (3) | US6103738A (es) |
EP (1) | EP0877734B1 (es) |
JP (1) | JP3070958B2 (es) |
KR (1) | KR19990076693A (es) |
AP (1) | AP715A (es) |
AR (1) | AR005166A1 (es) |
AT (1) | ATE194598T1 (es) |
AU (1) | AU708979B2 (es) |
BG (1) | BG102559A (es) |
BR (1) | BR9612263A (es) |
CA (1) | CA2236814C (es) |
CO (1) | CO4480106A1 (es) |
CZ (1) | CZ197698A3 (es) |
DE (1) | DE69609353T2 (es) |
DK (1) | DK0877734T3 (es) |
ES (1) | ES2151192T3 (es) |
GB (1) | GB9526546D0 (es) |
GR (1) | GR3034225T3 (es) |
HN (1) | HN1996000082A (es) |
HR (1) | HRP960616A2 (es) |
HU (1) | HUP9903560A3 (es) |
IS (1) | IS4731A (es) |
MA (1) | MA26414A1 (es) |
NO (1) | NO982913L (es) |
NZ (1) | NZ325248A (es) |
OA (1) | OA10703A (es) |
PL (1) | PL327610A1 (es) |
PT (1) | PT877734E (es) |
SK (1) | SK81698A3 (es) |
TN (1) | TNSN96161A1 (es) |
TR (1) | TR199801195T2 (es) |
WO (1) | WO1997023462A1 (es) |
YU (1) | YU68896A (es) |
ZA (1) | ZA9610784B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
GB9711220D0 (en) * | 1997-05-30 | 1997-07-23 | Isis Innovation | Antiarrhythmic agents |
GB9711650D0 (en) * | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
ES2251512T3 (es) * | 2000-08-31 | 2006-05-01 | F. Hoffmann-La Roche Ag | Derivados de quinazolina como antagonista adrenergicos alfa-1. |
BR0116662A (pt) * | 2001-01-02 | 2003-09-23 | Hoffmann La Roche | Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos |
US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US6734303B2 (en) | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
AU2003249212C1 (en) * | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
BR0314759A (pt) | 2002-09-26 | 2005-07-26 | Pfizer | Derivados de pirazol |
BRPI0409611A (pt) | 2003-04-23 | 2006-04-18 | Glaxo Group Ltd | derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas |
US20050124562A1 (en) * | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US20080279909A1 (en) * | 2006-05-12 | 2008-11-13 | Cleek Robert L | Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization |
US9114194B2 (en) * | 2006-05-12 | 2015-08-25 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having high biological activity following mechanical manipulation |
US8986713B2 (en) * | 2006-05-12 | 2015-03-24 | W. L. Gore & Associates, Inc. | Medical device capable of being compacted and expanded having anti-thrombin III binding activity |
US8496953B2 (en) * | 2006-05-12 | 2013-07-30 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having a high degree of biological activity following sterilization |
US8021677B2 (en) | 2006-05-12 | 2011-09-20 | Gore Enterprise Holdings, Inc. | Immobilized biologically active entities having a high degree of biological activity |
JP5577104B2 (ja) * | 2007-03-14 | 2014-08-20 | エクセリクシス パテント カンパニー エルエルシー | ヘッジホッグ経路の阻害剤 |
ES2404076T3 (es) | 2008-11-14 | 2013-05-23 | F. Hoffmann-La Roche Ag | Derivados quinazolina como antagonistas del receptor de NK3 |
CN110818633A (zh) | 2009-01-16 | 2020-02-21 | 埃克塞里艾克西斯公司 | 一种苹果酸盐及其晶型 |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
EP2421857B1 (en) * | 2009-03-23 | 2013-08-28 | Cipla Limited | Process for the preparation of doxazosin and salts thereof |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
LT3575288T (lt) | 2009-09-03 | 2021-12-10 | Bristol-Myers Squibb Company | Chinazolinai kaip kalio jonų kanalų inhibitoriai |
US8591932B2 (en) | 2009-09-17 | 2013-11-26 | W. L. Gore & Associates, Inc. | Heparin entities and methods of use |
BR112013023241B1 (pt) | 2011-03-11 | 2019-07-02 | W. L. Gore & Associates, Inc. | Molécula de polímero catiônico hiper ramificado e dispositivo |
US20140309184A1 (en) * | 2011-09-21 | 2014-10-16 | University Of South Alabama | Methods and compositions for the treatment of ovarian cancer |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
RU2695815C9 (ru) * | 2014-03-24 | 2019-10-28 | Гуандун Чжуншэн Фармасьютикал Ко., Лтд | Хинолиновые производные в качестве ингибиторов smo |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
EP3939591A1 (en) | 2016-06-27 | 2022-01-19 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR79603B (es) * | 1982-07-24 | 1984-10-31 | Pfizer | |
GB8506174D0 (en) * | 1985-03-09 | 1985-04-11 | Pfizer Ltd | 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives |
GB8814458D0 (en) * | 1988-06-17 | 1988-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
-
1995
- 1995-12-23 NZ NZ325248A patent/NZ325248A/en unknown
- 1995-12-23 GB GBGB9526546.8A patent/GB9526546D0/en active Pending
-
1996
- 1996-12-05 PL PL96327610A patent/PL327610A1/xx unknown
- 1996-12-05 WO PCT/EP1996/005609 patent/WO1997023462A1/en not_active Application Discontinuation
- 1996-12-05 SK SK816-98A patent/SK81698A3/sk unknown
- 1996-12-05 DE DE69609353T patent/DE69609353T2/de not_active Expired - Fee Related
- 1996-12-05 HU HU9903560A patent/HUP9903560A3/hu unknown
- 1996-12-05 TR TR1998/01195T patent/TR199801195T2/xx unknown
- 1996-12-05 ES ES96943954T patent/ES2151192T3/es not_active Expired - Lifetime
- 1996-12-05 JP JP9523272A patent/JP3070958B2/ja not_active Expired - Fee Related
- 1996-12-05 AU AU13719/97A patent/AU708979B2/en not_active Ceased
- 1996-12-05 DK DK96943954T patent/DK0877734T3/da active
- 1996-12-05 BR BR9612263A patent/BR9612263A/pt not_active Application Discontinuation
- 1996-12-05 CZ CZ981976A patent/CZ197698A3/cs unknown
- 1996-12-05 US US09/091,370 patent/US6103738A/en not_active Expired - Fee Related
- 1996-12-05 KR KR1019980704806A patent/KR19990076693A/ko not_active Application Discontinuation
- 1996-12-05 PT PT96943954T patent/PT877734E/pt unknown
- 1996-12-05 EP EP96943954A patent/EP0877734B1/en not_active Expired - Lifetime
- 1996-12-05 AT AT96943954T patent/ATE194598T1/de not_active IP Right Cessation
- 1996-12-05 CA CA002236814A patent/CA2236814C/en not_active Expired - Fee Related
- 1996-12-12 HN HN1996000082A patent/HN1996000082A/es unknown
- 1996-12-18 TN TNTNSN96161A patent/TNSN96161A1/fr unknown
- 1996-12-18 MA MA24433A patent/MA26414A1/fr unknown
- 1996-12-19 AP APAP/P/1996/000900A patent/AP715A/en active
- 1996-12-20 ZA ZA9610784A patent/ZA9610784B/xx unknown
- 1996-12-20 AR ARP960105804A patent/AR005166A1/es unknown
- 1996-12-20 YU YU68896A patent/YU68896A/sh unknown
- 1996-12-20 CO CO96066994A patent/CO4480106A1/es unknown
- 1996-12-23 HR HR9526546.8A patent/HRP960616A2/xx not_active Application Discontinuation
-
1998
- 1998-04-29 IS IS4731A patent/IS4731A/is unknown
- 1998-06-18 BG BG102559A patent/BG102559A/xx unknown
- 1998-06-22 NO NO982913A patent/NO982913L/no not_active Application Discontinuation
- 1998-06-23 OA OA9800092A patent/OA10703A/en unknown
-
2000
- 2000-08-17 GR GR20000401910T patent/GR3034225T3/el not_active IP Right Cessation
-
2001
- 2001-03-19 US US09/812,083 patent/US6642242B2/en not_active Expired - Fee Related
-
2003
- 2003-06-04 US US10/455,546 patent/US6750214B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4480106A1 (es) | Compuestos de quinolina y quinazolina utiles en terapia | |
PA8444301A1 (es) | Compuestos de quinolina y de quinazolina utiles en terapia | |
ES2123829T3 (es) | Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas. | |
GT200000011A (es) | Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales. | |
CO4930259A1 (es) | Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen | |
ES2040838T3 (es) | Compuestos piperazinil-heterociclicos. | |
PA8463001A1 (es) | Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p | |
ES2161290T3 (es) | Derivados de quinazolina. | |
ES2164889T3 (es) | Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas. | |
PE12697A1 (es) | Compuestos heterociclicos, su preparacion y su uso | |
AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
ES2062974T3 (es) | Compuestos de cefalosporina, procedimientos para su preparacion y agentes antibacterianos. | |
SV2002000231A (es) | Compuestos 2,4,-diaminopirimidina utiles como inmunosupresores ref. pc10547/20083/bb | |
DE69820159D1 (de) | Therapeutisch nützliche Chinoline und Quinazoline | |
NO985981D0 (no) | Insulinpreparater som inneholder NaCl | |
ES2160106T3 (es) | Derivados de la quinazolina. | |
ES2071663T3 (es) | Analogo de fluoxetina. | |
ES2182114T3 (es) | Derivados azabiciclicos de la carbamoiloxi-multilina para empleo antibacteriano. | |
AR031196A1 (es) | Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados | |
ES2158861T3 (es) | 4-imidometil-1-(2'-fenil-2'-oxoetil)-piperidinas como inhibidores de los receptores 5ht2 de la serotonina, su preparacion y sus aplicaciones terapeuticas. | |
ES2132761T3 (es) | Derivados del acido piperidin acetico utiles como antagonistas del fibrinogeno. | |
ES2059931T3 (es) | Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular. | |
PA8550301A1 (es) | Proceso de produccion de quinazolina | |
DE69228307T2 (de) | Imidazo(1,2-c)chinazolinderivate als antihypertensive und antidysurie | |
ES2162686T3 (es) | Nuevos derivados carboxamidas ciclicos sustituidos por carboxi. |